• 1
    Nieuwenhuis MG, Kirkels JH. Predictability and other aspects of post-transplant diabetes mellitus in heart transplant recipients. J Heart Lung Transplant 2001; 20: 703708.
  • 2
    First MR, Gerber DA, Hariharan S et al. Posttransplant diabetes mellitus in kidney allograft recipients. incidence, risk factors, and management. Transplantation 2002; 73: 379386.
  • 3
    Greenspan LC, Gitelman SE, Leong MA et al. Increased incidence in post-transplant diabetes mellitus in children: a case-control analysis. Pediatr Nephrol 2002; 17: 15.
  • 4
    Al-Uzri A, Stablein DM, Cohn R et al. Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 72: 10201024.
  • 5
    Paolillo JA, Boyle GJ, Law YM et al. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. Transplantation 2001; 71: 252256.
  • 6
    Shapiro R, Scantlebury VP, Jordan ML et al. Tacrolimus in pediatric renal transplantation. Transplantation 1996; 62: 17521758.
  • 7
    Hathaway DK, Tolley EA, Blakely ML et al. Development of an index to predict posttransplant diabetes mellitus. Clin Transplant 1993; 7: 330338.
  • 8
    Miles AM, Sumrani N, Horowitz R et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 1998; 65: 380384.
  • 9
    Boudreaux JP, McHugh L, Canafax DM et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987; 44: 376381.
  • 10
    Clark MJ, Jr, Sterrett JJ, Carson DS et al. Diabetes guidelines: a summary and comparison of the recommendations of the American Diabetes Association, Veterans Health Administration, and American Association of Clinical Endocrinologists. Clin Ther 2000; 22: 899910 discussion 898.
  • 11
    Meier-Kriesche HU, Arndorfer JA, Kaplan B et al. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 2002; 73: 7074.
  • 12
    Barlow SE, Dietz WH. Management of child and adolescent obesity: summary and recommendations based on reports from pediatricians, pediatric nurse practitioners, and registered dietitians. Pediatrics 2002; 110 (1 Part 2): 236238.
  • 13
    Hjelmesaeth J, Hartmann A, Kofstad J et al. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant 2001; 16: 829835.
  • 14
    Midtvedt K, Hartmann A, Hjelmesaeth J et al. Insulin resistance is a common denominator of post-transplant diabetes mellitus and impaired glucose tolerance in renal transplant recipients. Nephrol Dial Transplant 1998; 13: 427431.
  • 15
    Lohmann T, List C, Lamesch P et al. Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunosuppressive therapy by FK506/tacrolimus. Exp Clin Endocrinol Diabetes 2000; 108: 347352.
  • 16
    Wakugami T, Islam MR, Higa S et al. Effect of FK506 on the development of diabetes in BB rats in comparison with that of cyclosporin. Tohoku J Exp Med 1993; 169: 2129.
  • 17
    Moxey-Mims MM, Kay C, Light JA et al. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506). Transplantation 1998; 65: 617619.
  • 18
    Furth S, Neu A, Colombani P et al. Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients. Pediatr Nephrol 1996; 10: 6466.
  • 19
    Toyonaga T, Kondo T, Miyamura N et al. Sudden onset of diabetes with ketoacidosis in a patient treated with FK506/tacrolimus. Diabetes Res Clin Pract 2002; 56: 1318.
  • 20
    Yoshioka K, Sato T, Okada N et al. Post-transplant diabetes with anti-glutamic acid decarboxylase antibody during tacrolimus therapy. Diabetes Res Clin Pract 1998; 42: 8589.